Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Equivalents (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Cash & Equivalents for 14 consecutive years, with $28.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 11.03% year-over-year to $28.6 million, compared with a TTM value of $28.6 million through Dec 2025, up 11.03%, and an annual FY2025 reading of $28.6 million, up 11.03% over the prior year.
  • Cash & Equivalents was $28.6 million for Q4 2025 at Heron Therapeutics, down from $43.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $191.2 million in Q2 2021 and bottomed at $2.0 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $39.1 million, with a median of $22.5 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents skyrocketed 2415.43% in 2021, then tumbled 96.49% in 2023.
  • Year by year, Cash & Equivalents stood at $4.5 million in 2021, then surged by 241.42% to $15.4 million in 2022, then plummeted by 65.5% to $5.3 million in 2023, then skyrocketed by 386.83% to $25.8 million in 2024, then grew by 11.03% to $28.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for HRTX at $28.6 million in Q4 2025, $43.1 million in Q3 2025, and $2.6 million in Q2 2025.